Clinical trial
Pemetrexed and Gemcitabine in Patients With Advanced Head and Neck Cancer
NCT00394147 · Fox Chase Cancer Center, Other · Terminated
Key facts
| NCT number | NCT00394147 |
|---|---|
| Title | Pemetrexed and Gemcitabine in Patients With Advanced Head and Neck Cancer |
| Official title | Phase II Trial of Pemetrexed and Gemcitabine in Patients With Advanced Head and Neck Cancer (SCCHN) |
| Lead sponsor | Fox Chase Cancer Center, Other |
| Collaborators | Eli Lilly and Company Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Head and Neck Cancer |
| Intervention type | Drug |
| Interventions | pemetrexed, gemcitabine |
| Enrollment | 17 |
| Start date | Oct 1, 2006 |
| Primary completion | Aug 1, 2008 |
| Completion | Dec 1, 2009 |
| First posted | Oct 31, 2006 |
| Last update posted | Aug 5, 2022 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: